Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2941-2950

  Laderoute, Keith R ^a   Alarcon, Rodolfo M ^b   Brody, Michael D ^a   Calaoagan, Joy M ^a   Chen, Eunice Y ^b   Knapp, A Merrill ^a   Yun, Zhong ^b   Denko, Nicholas C ^b   Giaccia, Amato J ^b  

^a SRI INTERNATIONAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; THROMBOSPONDIN 1; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL HYPOXIA; CELL TRANSFORMATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL HYPOXIA; CELLS, CULTURED; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; LYMPHOKINES; MICE; MICE, SCID; THROMBOSPONDIN 1; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033924882     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Vaupel, P., Kallinowski, F., and Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 49: 6449-6465, 1989.
2. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
3. Graeber, T., Osmanian, C., Jacks, T., Housman, D., Koch, C., Lowe, S., and Giaccia, A. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (Lond.), 379: 88-91, 1996.
4. Ausserer, W. A., Bourrat-Floeck, B., Green, C. J., Laderoute, K. R., and Sutherland, R. M. Regulation of c-jun expression during hypoxic and low-glucose stress. Mol. Cell. Biol., 14: 5032-5042, 1994.
5. Müller, J. M., Krauss, B., Kaltschmidt, C., Baeuerle, P. A., and Rupec, R. A. Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway. J. Biol. Chem., 272: 23435-23439, 1997.
6. Laderoute, K. R., Mendonca, H. L., Calaoagan, J. M., Knapp, A. M., Giaccia, A. J., and Stork, P. J. S. Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible SAPK/JNK activity. J. Biol. Chem., 274: 12890-12897, 1999.
7. Reynolds, T. Y., Rockwell, S., and Glazer, P. M. Genetic instability induced by the tumor microenvironment. Cancer Res., 56: 5754-5757, 1996.
8. Coquelle, A., Toledo, F., Stern, S., Bieth, A., and Debatisse, M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol. Cell, 2: 259-265, 1998.
9. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
10. Mazure, N. M., Chen, E. Y., Yeh, P., Mivechi, N., Laderoute, K. R., and Giaccia, A. J. Oncogenic transformation and hypoxia synergistically act to modulate VEGF expression. Cancer Res., 56: 3436-3440, 1996.
11. Naik, P., Karrim, J., and Hanahan, D. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev., 10: 2105-2116, 1996.
12. Bornstein, P., and Sage, E. H. Thrombospondins. In: E. Ruoslahti and E. Engvall (eds.), Extracellular Matrix Components, pp. 62-85. San Diego, CA: Academic Press, 1994.
13. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79: 185-188, 1994.
14. Volpert, O. V., Tolsma, S. S., Pellerin, S., Feige, J., Chen, H., Mosher, D. F., and Bouck, N. Inhibition of angiogenesis by thrombospondin-2. Biochem. Biophys. Res. Commun., 217: 326-332, 1995.
15. Volpert, O. V., Stellmach, V., and Bouck, N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res. Treat., 36: 119-126, 1995.
16. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
17. Volpert, O. V., Dameron, K. M., and Bouck, N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene, 14: 1495-1502, 1997.
18. Campbell, S. C., Volpert, O. V., Ivanovich, M., and Bouck, N. P. Molecular mediators of angiogenesis in bladder cancer. Cancer Res., 58: 1298-1304, 1998.
19. Volpert, O. V., Lawler, J., and Bouck, N. P. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc. Natl. Acad. Sci. USA, 95: 6343-6348, 1998.
20. Tuszynski, G. P., and Nicosia, R. F. The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays, 18: 71-76, 1996.
21. Wang, T. N., Qian, X., Granick, M. S., Solomon, M. P., Rothman, V. L., Berger, D. H., and Tuszynski, G. P. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J. Surg. Res., 63: 39-43, 1996.
22. Bernstein, P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol., 130: 503-506, 1995.
23. Roberts, D. D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J., 10: 1183-1191, 1996.
24. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Washington, DC), 265: 1582-1584, 1994.
25. Bleuel, K., Popp, S., Fusenig, N. E., Stanbridge, E. J., and Boukamp, P. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc. Natl. Acad. Sci. USA, 96: 2065-2070, 1999.
26. Streit, M., Velasco, P., Brown, L. F., Skobe, M., Richard, L., Riccardi, L., Lawler, J., and Detmar, M. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am. J. Pathol., 155: 441-452, 1999.
27. Mettouchi, A., Cabon, F., Montreau, N., Vernier, P., Mercier, G., Blangy, D., Tricoire, H., Vigier, P., and Binétruy, B. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J., 13: 5668-5678, 1994.
28. Slack, J. L., and Bornstein, P. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1. Cell Growth Differ., 5: 1373-1380, 1994.
29. Tikhonenko, A. T., Black, D. J., and Linial, M. L. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1. a possible tumor suppressor gene. J. Biol. Chem., 271: 30741-30747, 1996.
30. Li, Q., Ahuja, N., Burger, P. C., and Issa, J. P. Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene, 18: 3284-3289, 1999.
31. 1 phase checkpoint by low oxygen conditions is independent of p53 status. Mol. Cell. Biol., 14: 6264-6277, 1994.
32. Mukhopadhyay, D., Tsiokas, L., Zhou, X-M., Foster, D., Brugge, J. S., and Sukhatme, V. P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature (Lond.), 375: 577-581, 1995.
33. Levy, A. P., Levy, N. S., and Goldberg, M. A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem., 271: 2746-2753, 1996.
34. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. Induction of vascular endothelial cell growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia-inducible factor-1 transcriptional element. Blood, 90: 3322-3331, 1997.
35. Stein, I., Itin, A., Einat, P., Skaliter, R., Grossman, Z., and Keshet, E. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol. Cell. Biol., 18: 3112-3119, 1998.
36. Waleh, N. S., Brody, M. D., Knapp, A. M., Mendonca, H. L., Lord, E. M., Koch, C. J., Laderoute, K. R., and Sutherland, R. M. Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker. Cancer Res., 55: 6222-6226, 1995.
37. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirsawa, S., Sasazuki, T., and Kerbel, R. S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55: 4575-4580, 1995.
38. Raleigh, J. A., Calkins-Adams, D. P., Rinker, L. H., Ballenger, C. A., Weissler, M. C., Fowler, W. C., Jr., Novotny, D. B., and Varia, M. A. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res, 58: 3765-3768, 1998.
39. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 16: 4604-4613, 1996.
40. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., and Neckers, L. M. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature (Lond.), 392: 405-408, 1998.
41. Blagosklonny, M. V., An, W. G., Romanova, L. Y., Trepel, J., Fojo, T., and Neckers, L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem., 273: 11995-11998, 1998.
42. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
43. Alarcon, R. M., Rupnow, B. A., Graeber, T. G., Knox, S. J., and Giaccia, A. J. Modulation of c-Myc activity and apoptosis in vivo. Cancer Res., 56: 4315-4319, 1996.
44. Kim, C. Y., Tsai, M. H., Osmanian, C., Graeber, T. G., Lee, J. E., Giffard, R. G., DiPaolo, J. A., Peehl, D. M., and Giaccia, A. J. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res., 57: 4200-4204, 1997.
45. Hierck, B. P., Iperen, L. V., Gittenberger-De Groot, A. C., and Poelmann, R. E. Modified indirect immunodetection allows study of murine tissue with mouse monoclonal antibodies. J. Histochem. Cytochem., 42: 1499-1502, 1994.
46. Laderoute, K. R., Grant, T. D., Murphy, B. J., and Sutherland, R. M. Enhancement of epidermal growth factor receptor synthesis in A431 human squamous carcinoma cells exposed to low levels of oxygen. Int. J. Cancer, 42: 1-5, 1992.
47. Framson, P., and Bornstein, P. A serum response element and a binding site for NF-Y mediate the serum response of the human thrombospondin 1 gene. J. Biol. Chem., 268: 4989-4996, 1993.
48. Donoviel, D. B., Framson, P., Eldridge, C. F., Cooke, M., Kobayashi, S., and Bornstein, P. Structural analysis and expression of the human thrombospondin gene promoter. J. Biol. Chem., 263: 18590-18593, 1988.
49. Zabrenetzky, V., Harris, C. C., Steeg, P. S., and Roberts, D. D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer, 59: 191-195, 1994.
50. 2 tension. Am. J. Physiol., 271: C1172-C1180, 1996.
51. Nozue, M., Lee, I., Yuan, F., Teicher, B. A., Brizel, D. M., Dewhirst, M. W., Milross, C. G., Milas, L., Song, C. W., Thomas, C. D., Guichard, M., Evans, S. M., Koch, C. J., Lord, E. M., Jain, R. K., and Suit, H. D. Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker. J. Surg. Oncol., 66: 30-38, 1997.
52. Evans, S. M., Jenkins, W. T., Joiner, B., Lord, E. M., and Koch, C. J. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res., 56: 405-411, 1996.
53. Lee, J., Siemann, D. W., Koch, C. J., and Lord, E. M. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int. J. Cancer, 67: 372-378, 1996.
54. Shingu, T., and Bornstein, P. Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene. J. Biol. Chem., 269: 32551-32557, 1994.
55. Phelan, M. W., Forman, L. W., Perrine, S. P., and Faller, D. V. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J. Lab. Clin. Med., 132: 519-529, 1998.
56. Rangan, S. R. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer (Phila.), 29: 117-121, 1972.
57. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., and Dewhirst, M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res., 56: 941-943, 1996.
58. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
59. Nordsmark, M., Overgaard, M., and Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol., 41: 31-39, 1996.
60. Rupec, R. A., and Baeuerle, P. A. The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-κB. Eur. J. Biochem., 234: 632-640, 1995.
61. Jiang, B., Agani, F., Passaniti, A., and Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res., 57: 5328-5335, 1997.
62. Wenger, R. H., and Gassmann, M. Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem., 378: 609-616, 1997.
63. 2 homeostasis. Curr. Opin. Genet. Dev., 8: 588-594, 1998.
64. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., and Ratcliffe, P. J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA, 94: 8104-8109, 1997.
65. Carmeliet, P., Dor, Y., Herbert, J., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., and Collen, K. E. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature (Lond.), 394: 485-490, 1998.
66. Ryan, H., Lo, J., and Johnson, R. S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J., 17: 3005-3015, 1998.
67. Bouck, N. p53 and angiogenesis. Biochim. Biophys. Acta, 1287: 63-66, 1996.
68. Mukhopadhyay, D., Tsiokas, L., and Sukhatme, V. P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res., 55: 6161-6165, 1995.
69. Agani, F., Kirsch, D. G., Friedman, S. L., Kastan, M. B., and Semenza, G. L. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Res., 57: 4474-4477, 1997.
70. Wenger, R. H., Camenisch, G., Desbaillets, I., Chilov, D., and Gassmann, M. Up-regulation of hypoxia-inducible factor-1α is not sufficient for hypoxic/anoxic p53 induction. Cancer Res., 58: 5678-5680, 1998.
71. Heacock, C. S., and Sutherland, R. M. Enhanced synthesis of stress proteins caused by hypoxia and relation to altered cell growth and metabolism. Br. J. Cancer, 62: 217-225, 1990.
72. Kraggerud, S. M., Sandvik, J. A., and Pettersen, E. O. Regulation of protein synthesis in human cells exposed to extreme hypoxia. Anticancer Res., 15: 683-686, 1995.
73. Bein, K., Ware, J. A., and Simons, M. Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. J. Biol. Chem., 272: 21423-21429, 1998.
74. Sheibani, N., and Frazier, W. A. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett., 107: 45-52, 1996.
75. Fusenig, N. E., and Boukamp, P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol. Carcinog., 23: 144-158, 1998.
76. Dejong, V., Degeorges, A., Filleur, S., Ait-Si-Ali, S., Mettouchi, A., Bornstein, P., Binétruy, B., and Cabon, F. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun. Oncogene, 18: 3143-3151, 1999.